ArticleDiscover oncology2026
Impact of baseline nutritional and inflammatory markers on safety and efficacy of immune checkpoint inhibitors in cancer patients: a retrospective, monocentric study.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but predictive biomarkers of adverse events and outcomes remain limited. Recently, nutritional and inflammatory markers have emerged as potentially predictors of ICI toxicity and efficacy. MATERIALS AND
methodsIn this retrospective, monocentric study we evaluated the impact of baseline nutritional and inflammatory markers on ICI safety, activity and efficacy in patients affected by solid tumors treated with mono-immunotherapy. Baseline clinical, nutritional, and inflammatory parameters - including BMI, weight loss, albumin, prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) - were analyzed in relation to immune-related adverse events (irAEs), best response, progression-free survival (PFS), and overall survival (OS).
resultsBetween 2015 and 2021, 297 patients were included. Median age was 67 (range: 32–91), with 200 (67.3%) patients being male and 218 patients affected by either skin melanoma (41.8%) or lung cancer (31.7%). In 87% of cases, ICI was initiated with palliative intent. Univariate analysis showed associations between high PNI, low NLR, female sex, and first treatment line with increased risk of all-grade irAEs, while no factor predicted grade ≥ 3 toxicity. Higher BMI and receiving immunotherapy as first treatment line were associated with improved response rate and longer OS, while hypoalbuminemia, hyperglicemia, low PNI, and high NLR correlated with worse survival outcomes. In multivariate models, only receiving immunotherapy as first treatment line independently predicted better objective response (HR 0.55) and longer PFS (HR 0.57), while high NLR independently predicted shorter OS (HR 1.93).
conclusionNutritional and inflammation parameters represent new potential biomarkers which could help reshaping treatment with ICI in cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.